StockData
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc (XFOR) stock

XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30
$3.00+0.04 (+1.35%)

Close on Nov 20, 2026Market cap $297.44MP/E –Yield –

X4 Pharmaceuticals gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

X4 Pharmaceuticals's gross profit for the twelve months ending Sep 30, 2026 was $6.81M, up 136060.0% year over year. For fiscal 2025 it was $743.00K, down 58.8% from the year before.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$743.00K-58.8%
FY2024Dec 31, 2024$1.80M–
FY2023Dec 31, 2023$0–
FY2022Dec 31, 2022$0–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$2.29M+83.1%
Q2 FY2026Jun 30, 2026$783.00K-43.0%
Q1 FY2026Mar 31, 2026$1.90M–
Q4 FY2025Dec 31, 2025$1.84M+53.3%
Q3 FY2025Sep 30, 2025$1.25M+275.1%
Q2 FY2025Jun 30, 2025$1.37M+365.8%
Q1 FY2025Mar 31, 2025-$3.82M–
Q4 FY2024Dec 31, 2024$1.20M–
Q3 FY2024Sep 30, 2024$333.00K–
Q2 FY2024Jun 30, 2024$295.00K–
Q1 FY2024Mar 31, 2024$0–
Q2 FY2023Jun 30, 2023$0–

More X4 Pharmaceuticals figures

See a number that looks wrong?